Fig. 1: In vivo depletion of the dysfunctional CD150^high HSCs reduces myeloid differentiation bias and mitigates aging-associated platelet increase in old mice.

a, b Specific elimination of CD150^high HSCs by careful titration of the CD150-SAP complex concentration. The cell number (a) and percentage (b) of CD45.1⁺ and CD45.2⁺ cells were quantified after 3-day treatment. c Percentage of HSCs in the bone marrow 3 weeks post-treatment. d Distribution of HSCs based on CD150 expression levels in mice with or without in vivo CD150-SAP treatment. HSCs were evenly divided into 3 groups (CD150^low, CD150^med, and CD150^high) based on CD150 signal intensity in PBS-injected control mice, which served as a reference for CD150 level grouping. e Percentages of CD150^high, CD150^med, and CD150^low HSCs with or without in vivo CD150-SAP treatment. f Absolute numbers of CD150^high, CD150^med, and CD150^low HSCs per femur and tibia with or without CD150-SAP treatment. g H&E staining of bone marrow; scale bar, 20 μm. h Body weight changes following PBS or CD150-SAP injection. i Percentages of B cells, T cells, and myeloid cells in peripheral blood analyzed at different time points post-CD150-SAP treatment. j Complete blood count analysis performed 4 months post-CD150-SAP treatment. WBC, white blood cell; RBC, red blood cell. k Platelet counts measured at 4 months (left) and 5 months (right) post CD150-SAP treatment. Data are presented as mean ± SD. Statistical significance was determined by One-way ANOVA (c, j and k) or Two-way ANOVA (a, b, e, f, h and i) (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). Mouse number per group: n = 4 (c–g), n = 8–9 (h–k).